Pharmacokinetics of 40mg Dose of CS-866, an Angiotensin II Receptor Antagonist, in Essential Hypertensive Patients
|
Accession number;03A0865484
|
| Title;Pharmacokinetics of 40mg Dose of CS-866, an Angiotensin II Receptor Antagonist, in Essential Hypertensive Patients |
| Author;
KANADA SHIGETO
(Osakaiyakuhinrinshokaihatsushinryosho)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.19;NO.11;PAGE.1271-1282(2003)
|
| Figure&Table&Reference;FIG.2, TBL.12, REF.9 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;CS-866 at 40mg was given once daily for 7 days to 10 hypertensive patients, and the plasma levels of RNH- 6270, an active metabolite, was determined on the last day (Day 7). 1) As for hypotensive effect, the mean baseline blood pressure was 106.8.+-.7.4mmHg, which significantly decreased to 101.5.+-.9.5mmHg on Day 7. 2) Plasma levels of RNH-6270 reached their maximum value 2 hours after administration, then decreased with a half-life of about 6 hours, and after 24 hours, decreased to the level observed just before administration on Day 7. 3) For plasma PK parameters on Day 7, geometric averages of Cmax and AUC0-24 were 1008.5 (0.267) ng/mL and 7848.0 (0.301) ng/mL, respectively, and averages of tmax and t1/2 were 2.6 (1.0) hr and 6.0(1.0) hr. 4) Concerning the safety of CS-866, there were 6 cases of sleepiness and malaise in 2 patients; however, they were mild and disappeared without any treatment. Five cases of abnormal changes in laboratory data were confirmed, but all of them were found to be normalized in the follow-up. There were safety in the dose range CS-866 40mg once daily to essential hypertensive patients. (author abst.) |
|
|
|
Related Articles;
|
|
